Canaccord Genuity Group Cuts Definitive Healthcare (NASDAQ:DH) Price Target to $3.00

Definitive Healthcare (NASDAQ:DH) had its price target decreased by equities researchers at Canaccord Genuity Group from $4.00 to $3.00 in a report released on Friday,Benzinga reports. The firm currently has a “hold” rating on the stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 142.91% from the company’s current price.

DH has been the subject of a number of other research reports. Stephens reduced their price objective on Definitive Healthcare from $3.00 to $2.00 and set an “equal weight” rating for the company in a research report on Friday. Wall Street Zen cut Definitive Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 28th. Barclays reduced their price target on shares of Definitive Healthcare from $3.00 to $2.75 and set an “underweight” rating for the company in a research report on Monday, December 8th. Morgan Stanley reissued an “underperform” rating and issued a $3.50 price objective on shares of Definitive Healthcare in a report on Thursday, December 18th. Finally, William Blair upgraded shares of Definitive Healthcare to a “strong-buy” rating in a research report on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $3.52.

Definitive Healthcare Stock Performance

DH traded down $0.17 during mid-day trading on Friday, reaching $1.24. 374,026 shares of the company traded hands, compared to its average volume of 373,085. The company’s fifty day moving average price is $2.21 and its 200-day moving average price is $2.89. The stock has a market capitalization of $174.58 million, a P/E ratio of -0.74 and a beta of 1.59. The company has a quick ratio of 1.60, a current ratio of 1.60 and a debt-to-equity ratio of 0.41. Definitive Healthcare has a 52-week low of $1.14 and a 52-week high of $4.70.

Hedge Funds Weigh In On Definitive Healthcare

A number of hedge funds have recently made changes to their positions in DH. AQR Capital Management LLC lifted its holdings in Definitive Healthcare by 56.7% in the 1st quarter. AQR Capital Management LLC now owns 590,149 shares of the company’s stock worth $1,706,000 after purchasing an additional 213,562 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Definitive Healthcare by 564.2% during the first quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock worth $25,191,000 after acquiring an additional 7,404,363 shares during the last quarter. Jane Street Group LLC grew its stake in Definitive Healthcare by 166.0% during the first quarter. Jane Street Group LLC now owns 105,114 shares of the company’s stock valued at $304,000 after acquiring an additional 65,597 shares in the last quarter. CWM LLC boosted its holdings in shares of Definitive Healthcare by 212.4% during the 2nd quarter. CWM LLC now owns 24,498 shares of the company’s stock valued at $96,000 after purchasing an additional 16,657 shares during the last quarter. Finally, Bank of Montreal Can purchased a new position in shares of Definitive Healthcare during the second quarter valued at about $71,000. Institutional investors own 98.67% of the company’s stock.

More Definitive Healthcare News

Here are the key news stories impacting Definitive Healthcare this week:

• Positive Sentiment: Q4 revenue slightly beat expectations—reported about $61.5M, roughly in line or modestly above consensus, showing revenue resilience. Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2025
• Positive Sentiment: Cash position strengthened—cash & equivalents rose to roughly $163.6M (up ~55% YoY), providing liquidity runway. Definitive Healthcare Corp. (DH) stock falls on Q4 2025 Earnings
• Neutral Sentiment: Reported EPS of $0.06 for Q4, which matched the Zacks/consensus estimate (mixed context due to other metric moves). Definitive Healthcare Corp. (DH) Matches Q4 Earnings Estimates
• Neutral Sentiment: Consensus broker view remains cautious—average recommendation is “Hold.” Definitive Healthcare Corp. (NASDAQ:DH) Receives Average Recommendation of “Hold” from Brokerages
• Negative Sentiment: Company cut guidance for Q1 and FY‑2026: Q1 EPS guided to ~$0.03 vs. ~$0.05 consensus, and FY revenue guidance ($220–226M) and EPS (0.14–0.17) came in below Street forecasts—this is the primary driver of the selloff. Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2025
• Negative Sentiment: Stephens lowered its price target from $3.00 to $2.00 and moved to an “equal weight” rating, signaling reduced near‑term upside expectations. Benzinga
• Negative Sentiment: Underlying profitability metrics worsened: operating loss widened year‑over‑year, net loss and diluted EPS trends deteriorated, and operating cash flow weakened—these raise execution and margin concerns. Definitive Healthcare Corp. (DH) stock falls on Q4 2025 Earnings
• Negative Sentiment: Notable institutional selling in the latest quarter (several large funds reduced or exited positions), which can amplify near‑term downward pressure. Definitive Healthcare Corp. (DH) stock falls on Q4 2025 Earnings

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.